Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07023003

Postpartum Evaluation of Nifedipine and Enalapril for Hypertension

This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. This is an equivalence study- meaning it is not expected one medication is better than the other. Nifedipine has been shown to be better than another common blood pressure medicine, labetalol, for postpartum hypertension but enalapril which is also used worldwide to manage blood pressure postpartum, has not yet been evaluated or compared to nifedipine.

Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included. Our hypothesis is both medications are safe and effective in managing blood pressure and preventing readmission for hypertensive complications during the postpartum period so evaluating the rate of readmission is the primary goal of the study.

The only intervention of the trial will be to assign which medication the participant starts taking. Any decisions after that point- stopping medication, changing doses, additional medications, discharge from the hospital, etc, will all be at the discretion of the participant's primary provider.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • admitted for delivery by cesarean or vaginal delivery
  • 24 weeks gestation or greater
  • Pregnancy related hypertension(HTN) or chronic hypertension. Pregnancy related hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN in patients without CHTN.

Exclusion criteria

  • Absolute contraindication to either nifedipine or enalapril Relative contraindications will be reviewed with PI.
  • Persistent HR <60 or >110
  • Native language other than English

Treatment and study plan

Enalapril 10mg QD

Drug

Enalapril 10mg PO QD will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.

Other names: vasotec, enalaprilat, epaned

Nifedipine 30mg XL BID

Drug

Nifedipine 30mg XL BID will be given to manage postpartum hypertension. Duration of treatment to be dictated by primary provider.

Other names: adalat, procardia

Primary outcomes

  1. Hospital Readmission

    Time frame: Within 6 weeks of delivery

    Number of participants meeting criteria for hospital admission.

Study contacts

Contact information is provided by the study sponsor or research team.

Joshua Dahlke, MD

CONTACT

[email protected]

14028151970

Todd Lovgren, MD

CONTACT

[email protected]

14028151970

Sponsors and collaborators

Lead sponsor

Nebraska Methodist Health System

Other

Collaborators

  • Methodist Hospital Foundation

Registry information

Official study title

Postpartum Evaluation of Antihypertensives for Control of Hypertension: A Randomized Controlled Equivalence Study

Acronym: PEACE

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jun 15, 2025
Registry last updated
Oct 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.